16,17 Oral sodium valproate was previously believed to be useful for prophylaxis in chronic migraine.18 In recent years, however, intravenous sodium valproate has been studied as anti-migraine attack treatment with good response.19-23 Because of the side of effects and contraindications of Sumatriptan, we sought  to compare

the efficacy of Inhibitors,research,lifescience,medical sodium valproate and Sumatriptan in the treatment of acute migraine attacks. Patients and Methods This double-blind randomized clinical trial (IRCT Code: IRCT201108025943N4) was performed from December 2011 to May 2012 on 90 patients who referred to Shahid Sadoughi Hospital, Yazd, Iran. A simple randomized sampling procedure Inhibitors,research,lifescience,medical was performed on the basis of the study criteria using the “Random Allocation Software” program (figure 1). The patients, nurses administering the drugs, and those registering the signs and symptoms of the patients were blind to the medicine used in each group. The inclusion criteria were comprised of patients aged between 15 and 50 years with common migraine attacks and normal physical examinations. The exclusion criteria

consisted of hepatic disease, familial medical history of hepatic failure, special forms of migraine Inhibitors,research,lifescience,medical such as hemiplegic, basilar, ophthalmic, and retinal, uncontrolled hypertension, coronary artery disease, unstable angina, peripheral vascular disease, history of Inhibitors,research,lifescience,medical myocardial infarction, and pregnancy and lactation. Only 6 patients had classic migraine and were excluded in order to reduce bias. The patients were divided randomly into two equal groups. The mean headache severity in the patients before treatment as well as half an hour, one hour, and two hours after treatment was measured using the Verbal things Numerical Rating Scale (VNRS) ranging from zero to ten. Figure 1 The patient’s consort flow chart is illustrated above. After randomization of the patients Inhibitors,research,lifescience,medical into two groups, the first group was injected with 6 mg of Sumatriptan subcutaneously plus

200 cc of normal saline in 20 minutes and the second group received 400 mg of sodium valproate (Depakine, SANOFI AVENTIS, France) in 200 cc of normal saline (in 20 minutes) plus 2 cc of subcutaneous normal saline. Because intravenous sodium valproate in Iran is only available in 400-mg ampoules and previous studies have proved that 300-500 mg of intravenous sodium valproate Drug_discovery is sufficient for subsiding pain,18-20 we chose 400 mg of sodium valproate. Before and 2 hours after treatment, the patients’ vital signs were check precisely. Headache severity was measured on admission and thereafter half an hour, one hour, and two hours after treatment based on the VNRS in the two groups separately. Other symptoms, including photophobia, phonophobia, nausea, and vomiting,  were assayed on admission and then 2 hours after treatment.